Seattle Genetics Inc /wa (SGEN): Clay B Siegall , President and CEO of Seattle Genetics Inc /wa sold 31,269 shares on Sep 8, 2016. The Insider selling transaction was reported by the company on Sep 12, 2016 to the Securities and Exchange Commission. The shares were sold at $50.08 per share for a total value of $1,565,976.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 8, 2016, Clay B Siegall (President and CEO) sold 11,653 shares at $45.30 per share price.On Sep 8, 2016, Darren S Cline (EVP, Commercial) sold 5,397 shares at $46.01 per share price.Also, On Aug 24, 2016, Eric Dobmeier (Chief Operating Officer) sold 12,589 shares at $48.00 per share price.On Aug 22, 2016, Jonathan G Drachman (CMO & EVP, R & D) sold 3,991 shares at $46.59 per share price.
Seattle Genetics: On Monday, Sep 12, 2016 heightened volatility was witnessed in Seattle Genetics which led to swings in the share price. The shares opened for trading at $49.8 and hit $51.98 on the upside , eventually ending the session at $51.78, with a gain of 3.09% or 1.55 points. The heightened volatility saw the trading volume jump to 986,576 shares. The 52-week high of the share price is $51.98 and the company has a market cap of $7,276 M . The 52-week low of the share price is at $26.02.
Company has been under the radar of several Street Analysts.Seattle Genetics is Initiated by Morgan Stanley to Overweight. The Rating was issued on Sep 7, 2016.Seattle Genetics is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 53 from a previous price target of $48 .The Rating was issued on Jul 27, 2016.Seattle Genetics is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 130 from a previous price target of $125 .The Rating was issued on Jul 27, 2016.Seattle Genetics is Reiterated by SunTrust to Neutral and the brokerage firm has raised the Price Target to $ 38 from a previous price target of $34 .The Rating was issued on Jul 27, 2016.Seattle Genetics is Downgraded by Cantor Fitzgerald to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jul 27, 2016.
Seattle Genetics Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s marketed product ADCETRIS or brentuximab vedotin is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE) utilizing its technology. In addition to ADCETRIS the Company’s pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A SGN-CD19A SGN-LIV1A SGN-CD70A ASG-22ME and ASG-15ME and SEA-CD40 which is based on its sugar-engineered antibody (SEA) technology. In addition it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics’ sugar-engineered antibody (SEA) technology.